ABSTRACT
Due to its stimulatory potential for immunomodulatory CD4+ regulatory T (Treg) cells, low-dose interleukin-2 (IL-2) immunotherapy has recently gained considerable attention for treatment of various autoimmune diseases. Although early-stage clinical trials have correlated expansion of circulating Treg cells with clinical response to IL-2 treatment, detailed mechanistic data on responding Treg cell subsets are lacking. In this investigator-initiated phase-2 clinical trial of low-dose IL-2 immunotherapy in systemic lupus erythematosus (SLE) patients, we performed an in-depth study of circulating and cutaneous Treg cell subsets by imaging mass cytometry, high-parameter spectral flow cytometry, bulk and single-cell RNA sequencing with cellular indexing, and targeted serum proteomics. Low-dose IL-2 stimulated circulating Treg cells with skin-homing properties that appeared in the skin of SLE patients in close interaction with endothelial cells, suggestive of a gatekeeper function. Analysis of surface proteins and transcriptomes detected different IL-2-driven Treg cell programs, including highly proliferative CD38+ HLA-DR+, activated gut-homing CD38+, and skin-homing HLA-DR+ Treg cells. These data identify distinct and functionally characteristic Treg cell subsets in human blood and skin, including the Treg cell subsets most responsive to IL-2 immunotherapy, thus providing unprecedented insight into Treg cell biology during IL-2 treatment.
Competing Interest Statement
O.B. is a founder and shareholder of Anaveon AG, which develops IL-2 immunotherapies for cancer. O.B. and M.R. hold patents on improved IL-2 formulations. The other authors declare that they have no competing interests related to this manuscript.
Clinical Trial
NCT03312335
Funding Statement
The clinical trial and the translational studies were investigator-initiated and have been conducted independently of pharmaceutical companies. This work was supported by the Swiss National Science Foundation (310030-172978 and 310030-200669; to O.B.), Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie; to O.B.), Clinical Research Priority Program CYTIMM-Z of University of Zurich (to O.B.), Young Talents in Clinical Research Fellowship and a Project Grant by the Swiss Academy of Medical Sciences and G. & J. Bangerter-Rhyner Foundation (YTCR 32/18 and YTCR 08/20 to M.R.), and a Filling-the-Gap Fellowship by University of Zurich (to M.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Before initiation, the trial protocol was approved by the ethical committee of the Canton of Zurich, Switzerland (Swiss National Clinical Trials Portal registration number SNCTP000002372) and the Swiss Agency for Therapeutic Products Swissmedic.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw datasets generated by imaging mass cytometry as well as bulk and single-cell RNA sequencing will be deposited upon publication in a peer reviewed journal. All other data and materials are available upon request from the corresponding author after publication of this study in a peer reviewed journal.
